Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Stock Chart & Stats
$12.58
$0.30(1.54%)
At close: 4:00 PM EST
$12.58
$0.30(1.54%)
Day’s Range― - ―
52-Week Range$5.90 - $26.94
Previous CloseN/A
Volume216.17K
Average Volume (3M)2.76M
Market Cap
$808.26M
Enterprise Value-$154.44M
Total Cash (Recent Filing)$787.60M
Total Debt (Recent Filing)$9.50M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Mar 02, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding64,224,300
10 Day Avg. Volume3,498,707
30 Day Avg. Volume2,758,024
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.45
Price to Sales (P/S)5.23
P/FCF Ratio-5.28
Enterprise Value/Market Cap-0.19
Enterprise Value/Revenue-0.49
Enterprise Value/Gross Profit-0.49
Enterprise Value/Ebitda1.75
Forecast
1Y Price Target
$20.62Price Target Upside63.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$289.43M
Bulls Say, Bears Say
Bulls Say
Financial StabilityARVN ended the quarter with ~$788M in cash, expected to provide financial runway into the second half of 2028.
Innovative TreatmentsThe opportunity in Parkinson’s disease with ARV-102, targeting LRRK2, is promising.
Product DevelopmentARV-806 KRAS G12D degrader demonstrated greater than 25-fold potency over inhibitors, durable tumor regressions, and immune checkpoint synergy, positioning it as a differentiated entrant in one of oncology’s most valuable markets.
Bears Say
Competitive ChallengesRapidly evolving competitive landscape for HR+/HER2- mBC puts vepdegestrant at increasing risk of obsolescence.
Uncertainty In CommercializationThe out-licensing plan for the breast cancer drug vepdegestrant introduces significant uncertainty around the timing of commercialization and by whom.
Workforce ReductionsA 15% workforce reduction has been announced, on top of a previous 35% cut, as part of cost optimization measures.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $5.90 and its highest was $26.94 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $808.26M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Mar 02, 2026 which is in 91 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Nov 05, 2025. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.697 by $0.217.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.51.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 64,224,300 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.697. Following the earnings report the stock price went up 0.314%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.62 (63.91% Upside)
$20.62 (63.91% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 159.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $226.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed significant progress in Arvinas' clinical pipeline, particularly with ARV-102 and financial stability, but was tempered by a notable revenue decline and ongoing challenges in achieving efficacious exposure levels in some trials.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$20.62
▲(63.91% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.33% Insiders
23.13% Mutual Funds
32.70% Other Institutional Investors
27.98% Public Companies and
Individual Investors